Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Investor Presentation (March 2024)
32 slides from Oncosil Medical's investor presentation, Mar 20, 2024
Slide 1: OncoSil Limited: Developing pancreatic cancer treatment
For personal use only OncoSil Limited (ASX:OSL) Developing pancreatic cancer treatment Investor presentation – March 2024 Nigel Lange – CEO & Managing Director
Slide 2: Disclaimer
Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide a general overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presentation and the informat
Slide 3: OncoSil: Improving outcomes for people with pancreatic cancer
OncoSil: Improving outcomes for people with pancreatic cancer For personal use only OncoSil is a single-use brachytherapy device used to deliver a pre- determined dose of beta radiation directly into cancerous tissue. It is used in combination with chemotherapy. 3
Slide 4: An enhanced pancreatic cancer treatment finally at hand
An enhanced pancreatic cancer treatment finally at hand Changes in survival, 1971-72 to 2010-11 0% 25% 50% 75% 100% All Cancers For personal use only Incidence Testis Malignant Melanoma Prostate Hodgkin Lymphoma Breast Uterus • The prognosis for pancreatic cancer NHL Cervix patients has remained alm
Slide 5: OncoSil device revolutionises treatment of pancreatic cancer
OncoSilTM device revolutionises treatment of pancreatic cancer • The OncoSil device: A commercial-stage breakthrough device delivering targeted radiotherapy for For personal use only locally advanced pancreatic cancer • OncoSil device validation process well underway: Breakthrough designation rece
Slide 6: A primer on pancreatic cancer
For personal use only A primer on pancreatic cancer
Slide 7: Clinical Stages of Pancreatic Cancer
Clinical Stages of Pancreatic Cancer1 Tumour Size (LD) T1 2 cm T2 4 cm T3 Stage Stage Stage 21% Stage I Stage IIa Stage IIb None: N0 For personal use only Lymph Nodes (regional) RESECTABLE Cancer Common IA IB IIA bile duct patients diagnosed Pancrea Lymph 1–3: N1 Stage IIB [T1–3, N1] at Stage 1 and
Slide 8: Surgical Resection
Surgical Resection The only potentially curative treatment for pancreatic cancer1 RESECTABLE LOCALLY ADVANCED METASTATIC For personal use only % of patients at diagnosis 15% 30% 55% Surgical resection with Palliative therapies Palliative therapies curative intent (CT or ICT/CCRT)1,7,8,10 (usually CT
Slide 9: The OncoSil device
For personal use only device The OncoSilTM
Slide 10: OncoSil Device
OncoSil Device OncoSil is intended OncoSil is implanted directly for the treatment of locally advanced into a pancreatic tumour via For personal use only unresectable pancreatic cancer, injection under endoscopic in combination with gemcitabine-based ultrasound chemotherapy guidance 98% of all radia
Slide 11: FY 2024
For personal use only FY 2024
Slide 12: Achievements FY2024
Achievements FY2024 Commencement TRIPP study Innovation Funding Revised HDE dossier For personal use only of PancoSil trial now up to 12 (NUB) approval for 84 completed – currently – 1st patient sites with 17 German hospitals under final review prior to treated patients FDA submission included Comme
Slide 13: Validating OncoSil device's effectiveness
For personal use only Validating OncoSilTM device’s effectiveness
Slide 14: PanCO study demonstrated positive safety and efficacy signals
PanCO study demonstrated positive safety and efficacy signals Of the many encouraging outcomes from the PanCO study1, four are particularly important: For personal use only Established safety profile: No evidence suggesting any additional risk from using OncoSil 90.5% of OncoSil treated patients had
Slide 15: PanCO results showing compelling evidence of downstaging
PanCO results showing compelling evidence of downstaging OncoSil converted patients with unresectable locally advanced pancreatic cancer (LAPC) to surgically resectable, transforming their prognosis and substantially extending survival For personal use only Why is resection What did the PanCO study
Slide 16: TRIPP-FFX
TRIPP-FFX An open-label, multi-centre, randomized study of TaRgeted Intratumoural Placement of Phosphorous-32 (OncoSil ) in addition to FOLFIRINOX chemotherapy versus FOLFIRINOX chemotherapy alone in patients with unresectable locally advanced pancreatic For personal use only adenocarcinoma Objectiv
Slide 17: PANCOSIL (Investigator Initiated Study)
PANCOSIL (Investigator Initiated Study) Safety and feasibility of CT-guided percutaneous radionuclide therapy with the OncoSil device in patients with non-progressive locally advanced pancreatic cancer (PANCOSIL): an open-label, single-arm phase 1-2 feasibility study For personal use only To assess
Slide 18: Innovation Funding (NUB) in Germany
Innovation Funding (NUB) in Germany Funding for the use of the OncoSil device in Europe’s largest market For personal use only • German Institute for the Hospital Remuneration System (InEK) has authorized 84 German hospitals to negotiate funding for the OncoSil device classification under the innova
Slide 19: G-BA Fully Funded trial in Germany
G-BA Fully Funded trial in Germany Fully-funded trial leading to public insurance reimbursement For personal use only In March 2022, the Federal Joint Committee (G-BA) recommended a fully- OncoSil will receive revenue payments for the funded trial take place in Germany provision of the OncoSilTM dev
Slide 20: Corporate overview and leadership team
For personal use only Corporate overview and leadership team
Slide 21: Corporate Overview
Corporate Overview OncoSil Medical Limited | as at 19 March 20241 Major Shareholders (% of listed shares, as at 19 March 2024) Health Care – Pharmaceuticals, MRS SARAH CAMERON 11.99% For personal use only GICS: Biotechnology & Life Sciences (Life Sciences Tools & Services) MR PETER ANDREW PROKSA 4.1
Slide 22: Leadership team
Leadership team For personal use only Nigel Lange Douglas Cubbin Gabriel Liberatore Managing Director & CEO Non-executive Chairman Non-executive Director 30+ years experience in Experienced biopharmaceutical Dr Liberatore is an experienced medical device industry executive with over 30 years’ biopha
Slide 23: Leadership team
Leadership team For personal use only David Turner Henk Tissing Christian Dal Cin Renzo DiCarlo Dr Jon Bell MD Head of Medical Affairs Director of Clinical Development Chief Financial Officer Head of Transformation Chief Medical Officer 40+ years experience in 25+ years industry Christian has over 2
Slide 24: Commercialisation strategy & investment thesis
For personal use only Commercialisation strategy & investment thesis
Slide 25: Targeted commercialisation strategy deliverables
Targeted commercialisation strategy deliverables • G-BA progressed to commercial agreement For personal use only • FDA processes advanced • Re-engage TGA for approval in Australia • A steady uplift in the number of commercial treatments utilising OncoSilTM device • Additional distribution agreements
Slide 26: Site Training Update
Site Training Update Sites undertaking OncoSilTM Device treatments continue For personal use only to grow
Slide 27: OncoSil's investment thesis
OncoSil’s investment thesis For personal use only Development of OncoSilTM device Early commercialisation Regulatory approvals now now occurring work-in-progress A unique medical technology Hospitals utilising the OncoSil Green light on G-BA funding device continue to rise front could be a game chan
Slide 28: The OncoSil device is now in early-stage commercialisation
The OncosilTM device is now in early-stage commercialisation The OncoSil device, an effective treatment for locally advanced pancreatic cancer, is now penetrating its already large and continually growing target addressable markets For personal use only Many key components of commercialisation str
Slide 29: Developing pancreatic cancer treatment
For personal use only Developing pancreatic cancer treatment OncoSil Medical Limited (ASX:OSL) Investor Presentation March 2024 Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com Media & Investor Enquiries The Capital Network Julia Maguire P: +61 2 8999 3699 E: julia@thecapitalnetwork.co
Slide 30: Appendices
For personal use only Appendices
Slide 31: Optimal treatments of pancreatic cancer
Optimal treatments of pancreatic cancer Local Optimal Systemic For personal use only Treatment Outcomes Two Targets Surgery ± Radiation Chemotherapy ± Radiation 31
Slide 32: How the OncoSil device works
How the OncoSilTM device works For personal use only 32